Neuroaid for stroke patients

Neuroaid has just been approved by the Health Sciences Authority of Singapore for listing as a Chinese Proprietary Medicine. Neuroaid, also known as Danqi Jiaonang, is used in China as a medicine to bring about faster and fuller recovery for stroke patients during rehabilitation.

Clinical trials of Neuroaid involving some 800 stroke patients showed that it relieved their physical and neurological disabilities brought on by stroke. These trials were performed in China from 1999 to 2001 and also revealed that patients who were treated with Neuroaid were 2.11 times more likely than control patients to recover and regain normal daily function and speech.

To date, about half a million patients have been treated with Neuroaid in China. With a recommended course of treatment of three months, Neuroaid will be available at selected pharmacies in Singapore as well as from biopharma company, Moleac (www.moleac.net).